Isofluran-Piramal

Isoflurane, the active ingredient in Isofluran-Piramal, is a volatile anesthetic presented as a solution for inhalation use. It is employed for the induction and maintenance of general anesthesia in surgical patients. Isoflurane provides rapid onset of unconsciousness and analgesia, making it suitable for a wide range of operative procedures.

GNH USA supplies Isofluran-Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Isoflurane is a volatile anesthetic used in the central nervous system to produce general anesthesia.

- Induction of anesthesia: provides rapid loss of consciousness for surgical procedures. - Maintenance of anesthesia: sustains an unconscious state throughout the operation. - Surgical procedures: enables analgesia and muscle relaxation during operative interventions.

Common Side Effects: - Cough or airway irritation during administration. - Nausea and vomiting during emergence. - Hypotension due to vasodilation. - Tachycardia or mild arrhythmias.

Serious or Rare Side Effects: - Malignant hyperthermia in susceptible individuals. - Severe hypotension or cardiovascular collapse. - Hepatic or renal toxicity with prolonged exposure. - Seizures or severe central nervous system depression.

Isoflurane should be used only under qualified anesthesia supervision with appropriate monitoring.

- Patient assessment: evaluate airway, cardiovascular status, and susceptibility to malignant hyperthermia before use. - Concentration monitoring: adjust vaporizer settings to maintain target anesthetic depth. - Use with oxygen: ensure adequate oxygen delivery to prevent hypoxia. - Avoid in known malignant hyperthermia patients: select alternative anesthetic agents. - Store at ambient temperature: keep in original container, protect from light and moisture.

Isoflurane may interact with other drugs that affect the central nervous system or cardiovascular function.

Major Interactions (Avoid): - Co‑administration with other volatile anesthetics: additive CNS depression. - Potent CYP2E1 inhibitors: may alter Isoflurane metabolism. - Agents that trigger malignant hyperthermia (e.g., succinylcholine): increased risk of crisis.

Moderate Interactions (Monitor Closely): - Opioids: enhanced respiratory depression. - Benzodiazepines: increased sedation and delayed emergence. - Inhaled nitric oxide: potential hemodynamic effects. - Beta‑blockers: may exaggerate bradycardia.